These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38362553)

  • 1. The effect of carbohydrate intake on glycaemic control in individuals with type 1 diabetes: a randomised, open-label, crossover trial.
    Sterner Isaksson S; Ólafsdóttir AF; Ivarsson S; Imberg H; Toft E; Hallström S; Rosenqvist U; Ekström M; Lind M
    Lancet Reg Health Eur; 2024 Feb; 37():100799. PubMed ID: 38362553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A carbohydrate-reduced high-protein diet improves HbA
    Skytte MJ; Samkani A; Petersen AD; Thomsen MN; Astrup A; Chabanova E; Frystyk J; Holst JJ; Thomsen HS; Madsbad S; Larsen TM; Haugaard SB; Krarup T
    Diabetologia; 2019 Nov; 62(11):2066-2078. PubMed ID: 31338545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dietary carbohydrate restriction augments weight loss-induced improvements in glycaemic control and liver fat in individuals with type 2 diabetes: a randomised controlled trial.
    Thomsen MN; Skytte MJ; Samkani A; Carl MH; Weber P; Astrup A; Chabanova E; Fenger M; Frystyk J; Hartmann B; Holst JJ; Larsen TM; Madsbad S; Magkos F; Thomsen HS; Haugaard SB; Krarup T
    Diabetologia; 2022 Mar; 65(3):506-517. PubMed ID: 34993571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of a randomized cross-over study evaluating effects of carbohydrate intake on glycemic control in persons with type 1 diabetes.
    Sterner Isaksson S; Ólafsdóttir AF; Lind M
    Front Nutr; 2023; 10():1114317. PubMed ID: 36992911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flexible insulin therapy with a hybrid regimen of insulin degludec and continuous subcutaneous insulin infusion with pump suspension before exercise in physically active adults with type 1 diabetes (FIT Untethered): a single-centre, open-label, proof-of-concept, randomised crossover trial.
    Aronson R; Li A; Brown RE; McGaugh S; Riddell MC
    Lancet Diabetes Endocrinol; 2020 Jun; 8(6):511-523. PubMed ID: 32445738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial.
    Tauschmann M; Thabit H; Bally L; Allen JM; Hartnell S; Wilinska ME; Ruan Y; Sibayan J; Kollman C; Cheng P; Beck RW; Acerini CL; Evans ML; Dunger DB; Elleri D; Campbell F; Bergenstal RM; Criego A; Shah VN; Leelarathna L; Hovorka R;
    Lancet; 2018 Oct; 392(10155):1321-1329. PubMed ID: 30292578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: a pre-specified subgroup analysis of the IMPACT randomised controlled trial.
    Oskarsson P; Antuna R; Geelhoed-Duijvestijn P; Krӧger J; Weitgasser R; Bolinder J
    Diabetologia; 2018 Mar; 61(3):539-550. PubMed ID: 29273897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial.
    van Beers CA; DeVries JH; Kleijer SJ; Smits MM; Geelhoed-Duijvestijn PH; Kramer MH; Diamant M; Snoek FJ; Serné EH
    Lancet Diabetes Endocrinol; 2016 Nov; 4(11):893-902. PubMed ID: 27641781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial.
    Beck RW; Riddlesworth TD; Ruedy KJ; Kollman C; Ahmann AJ; Bergenstal RM; Bhargava A; Bode BW; Haller S; Kruger DF; McGill JB; Polonsky W; Price D; Toschi E;
    Lancet Diabetes Endocrinol; 2017 Sep; 5(9):700-708. PubMed ID: 28711468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009966. PubMed ID: 28238223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a low-carbohydrate diet in adults with type 1 diabetes management: A single arm non-randomised clinical trial.
    Turton JL; Brinkworth GD; Parker HM; Lim D; Lee K; Rush A; Johnson R; Rooney KB
    PLoS One; 2023; 18(7):e0288440. PubMed ID: 37432920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
    Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial.
    Heimbürger SMN; Hoe B; Nielsen CN; Bergmann NC; Hartmann B; Holst JJ; Vilsbøll T; Dejgaard TF; Christensen MB; Knop FK
    Diabetologia; 2021 Nov; 64(11):2425-2431. PubMed ID: 34405256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of professional-mode flash glucose monitoring, at 3-month intervals, in adults with type 2 diabetes in general practice (GP-OSMOTIC): a pragmatic, open-label, 12-month, randomised controlled trial.
    Furler J; O'Neal D; Speight J; Blackberry I; Manski-Nankervis JA; Thuraisingam S; de La Rue K; Ginnivan L; Doyle R; Holmes-Truscott E; Khunti K; Dalziel K; Chiang J; Audehm R; Kennedy M; Clark M; Jenkins A; Lake AJ; Januszewski AS; Catchpool M; Liew D; Clarke P; Best J
    Lancet Diabetes Endocrinol; 2020 Jan; 8(1):17-26. PubMed ID: 31862147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical effects of a carbohydrate-reduced high-protein diet on glycaemic variability in metformin-treated patients with type 2 diabetes mellitus: A randomised controlled study.
    Thomsen MN; Skytte MJ; Astrup A; Deacon CF; Holst JJ; Madsbad S; Krarup T; Haugaard SB; Samkani A
    Clin Nutr ESPEN; 2020 Oct; 39():46-52. PubMed ID: 32859328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
    Rosenstock J; Wysham C; Frías JP; Kaneko S; Lee CJ; Fernández Landó L; Mao H; Cui X; Karanikas CA; Thieu VT
    Lancet; 2021 Jul; 398(10295):143-155. PubMed ID: 34186022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous subcutaneous insulin infusion versus multiple daily injections in children and young people at diagnosis of type 1 diabetes: the SCIPI RCT.
    Blair J; McKay A; Ridyard C; Thornborough K; Bedson E; Peak M; Didi M; Annan F; Gregory JW; Hughes D; Gamble C
    Health Technol Assess; 2018 Aug; 22(42):1-112. PubMed ID: 30109847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial.
    Pieber TR; Arfelt KN; Cailleteau R; Hart M; Kar S; Mursic I; Svehlikova E; Urschitz M; Haahr H
    Diabetologia; 2023 Aug; 66(8):1413-1430. PubMed ID: 37308751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of low- and high-carbohydrate diets for type 2 diabetes management: a randomized trial.
    Tay J; Luscombe-Marsh ND; Thompson CH; Noakes M; Buckley JD; Wittert GA; Yancy WS; Brinkworth GD
    Am J Clin Nutr; 2015 Oct; 102(4):780-90. PubMed ID: 26224300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
    Rosenstock J; Frias J; Jastreboff AM; Du Y; Lou J; Gurbuz S; Thomas MK; Hartman ML; Haupt A; Milicevic Z; Coskun T
    Lancet; 2023 Aug; 402(10401):529-544. PubMed ID: 37385280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.